Bulk Pharmaceutical API Sources for OMACETAXINE MEPESUCCINATE

Bulk Pharmaceutical API Sources for OMACETAXINE MEPESUCCINATE

Vendor	Vendor Homepage	Vendor Sku	API Url
NIH Clinical Collection		SAM001246822
NovoSeek		285033
MolPort		MolPort-003-983-592
AAA Chemistry		AR-1K8685
ABI Chem		AC1L6273
ABI Chem		AC1Q5YWQ

Omacetaxine Mepesuccinate Bulk API Sources: Market Analysis

Last updated: February 19, 2026

This analysis identifies key manufacturers and suppliers of omacetaxine mepesuccinate bulk active pharmaceutical ingredient (API), evaluating their production capabilities, regulatory compliance, and market presence. The data is crucial for pharmaceutical companies seeking reliable sourcing for omacetaxine mepesuccinate, primarily used in the treatment of chronic myeloid leukemia (CML).

What are the Primary Manufacturers of Omacetaxine Mepesuccinate API?

The global supply of omacetaxine mepesuccinate API is concentrated among a limited number of specialized manufacturers. These entities possess the necessary synthesis expertise and adhere to stringent quality control standards required for pharmaceutical-grade API production.

• Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals International): Bausch Health, through its subsidiaries, holds a significant position in the omacetaxine mepesuccinate market, particularly as the originator or a key licensed manufacturer. Their capabilities include integrated API production and formulation.
• Contract Development and Manufacturing Organizations (CDMOs): Several CDMOs are involved in the synthesis of omacetaxine mepesuccinate. These organizations typically operate under contract for larger pharmaceutical companies and may not directly market the API under their own brand. Identifying specific CDMOs often requires direct inquiry due to contractual confidentiality. Examples of CDMOs with broad oncology API capabilities include Lonza, Catalent, and Siegfried. While these companies may not have omacetaxine mepesuccinate specifically listed in public portfolios, their expertise in complex small molecule synthesis makes them potential suppliers.
• Emerging Market Suppliers: Manufacturers in regions such as India and China are increasingly entering the generic API market. Companies specializing in nucleoside analogues and other complex cytotoxic agents are potential suppliers of omacetaxine mepesuccinate. However, thorough due diligence regarding their regulatory standing and quality systems is essential.

What are the Regulatory Requirements for Omacetaxine Mepesuccinate API Production?

Omacetaxine mepesuccinate API production is subject to rigorous regulatory oversight to ensure patient safety and product efficacy. Key regulatory frameworks and requirements include:

• Good Manufacturing Practices (GMP): Compliance with current Good Manufacturing Practices (cGMP) as defined by regulatory bodies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Japan's Pharmaceuticals and Medical Devices Agency (PMDA) is mandatory. GMP guidelines cover all aspects of production, including facility design, equipment validation, personnel training, raw material control, process validation, and quality assurance.
• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies. A DMF contains confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. Pharmaceutical companies reference these DMFs in their drug product applications. The availability and completeness of a DMF for omacetaxine mepesuccinate are critical for regulatory approval of finished drug products.
• ICH Guidelines: International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) guidelines, particularly ICH Q7 (Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients), are foundational. These guidelines standardize quality requirements across different regions.
• Impurity Profiling and Control: Rigorous control and characterization of impurities, including process-related impurities and degradation products, are essential. Regulatory submissions must include detailed information on impurity profiles and the analytical methods used for their detection and quantification.
• Stability Studies: Comprehensive stability studies demonstrating the API's shelf life under specified storage conditions are required. These studies assess degradation pathways and potential formation of new impurities over time.

What are the Key Quality and Purity Specifications for Omacetaxine Mepesuccinate API?

Omacetaxine mepesuccinate API must meet stringent quality and purity specifications to be suitable for pharmaceutical use. These specifications are typically defined in pharmacopoeial monographs (e.g., United States Pharmacopeia (USP), European Pharmacopoeia (Ph. Eur.)) or by the innovator company in their regulatory filings.

• Assay: The percentage of omacetaxine mepesuccinate in the API must fall within a defined range, typically >98.0%.
• Identification: Specific tests (e.g., Infrared Spectroscopy, Nuclear Magnetic Resonance Spectroscopy, High-Performance Liquid Chromatography (HPLC) retention time) confirm the identity of the API.
• Related Substances/Impurities: Limits are set for known and unknown impurities. These often include specific process impurities, starting material residues, and degradation products. For instance, USP monograph for omacetaxine mepesuccinate typically specifies limits for individual specified impurities (e.g., <0.10%) and total impurities (e.g., <0.50%).
• Water Content: Typically determined by Karl Fischer titration, the water content must be within a specified limit (e.g., <0.5%).
• Residual Solvents: Limits for residual organic solvents used during synthesis are established according to ICH Q3C guidelines.
• Heavy Metals: Content of heavy metals is controlled and must be below predefined limits.
• Chirality: As omacetaxine mepesuccinate is a chiral molecule, enantiomeric purity might be a critical parameter, though the mepesuccinate salt form inherently involves succinic acid, which is achiral. The active moiety, omacetaxine, is derived from a naturally occurring compound.
• Physical Characteristics: Properties such as particle size distribution, crystal form (polymorphism), and bulk density can influence the API's performance in downstream drug product manufacturing and are often specified.

What is the Market Landscape and Competitive Intensity for Omacetaxine Mepesuccinate API?

The market for omacetaxine mepesuccinate API is characterized by a relatively niche demand driven by the approved indications for the finished drug product (e.g., marketed as Synribo by Bausch Health).

• Innovator-Controlled Supply: Initially, the supply chain is heavily influenced by the innovator company (Bausch Health). They may produce the API internally or through exclusive contracts with CDMOs.
• Generic Competition: As patent protection diminishes, generic manufacturers may enter the market. This typically leads to increased competition among API suppliers, driving down prices and increasing the importance of cost-effective manufacturing and regulatory compliance.
• Limited Number of Suppliers: The complex synthesis pathway and specialized nature of omacetaxine mepesuccinate likely result in a limited number of qualified API manufacturers. This can lead to supply chain vulnerabilities if a primary supplier faces production issues or regulatory challenges.
• Geographic Concentration: API manufacturing may be concentrated in regions with established expertise in complex small molecule synthesis and strong regulatory track records.
• Pricing: Pricing is influenced by factors such as production volume, raw material costs, manufacturing complexity, regulatory compliance costs, and market competition. Innovator pricing is typically higher than generic API pricing.

What are the Key Considerations for Sourcing Omacetaxine Mepesuccinate API?

Pharmaceutical companies sourcing omacetaxine mepesuccinate API must conduct thorough due diligence to ensure supply chain security, product quality, and regulatory compliance.

• Supplier Qualification: This involves a comprehensive assessment of potential suppliers, including their manufacturing facilities, quality management systems, regulatory history (FDA inspections, EMA audits), and financial stability.
• Regulatory Support: Verify that the supplier has a comprehensive and up-to-date DMF filed with relevant regulatory agencies (e.g., FDA, EMA). The ability of the supplier to provide timely responses to regulatory queries is also critical.
• Quality Agreements: Establish robust quality agreements that clearly define roles, responsibilities, and expectations regarding quality control, change management, batch release, and issue resolution.
• Supply Chain Security and Redundancy: Assess the supplier's risk management strategies for supply chain disruptions (e.g., raw material shortages, geopolitical instability, natural disasters). Developing relationships with multiple qualified suppliers can mitigate risks.
• Technical Capabilities: Ensure the supplier has the technical expertise and capacity to consistently produce API meeting all required specifications, including impurity profiles and particle size.
• Cost-Effectiveness: While quality and reliability are paramount, competitive pricing is a key factor, especially for generic drug development.
• Intellectual Property (IP): For generic manufacturers, understanding the IP landscape related to omacetaxine mepesuccinate synthesis routes is crucial to avoid infringement.

What are the Future Trends in Omacetaxine Mepesuccinate API Sourcing?

Future trends in omacetaxine mepesuccinate API sourcing will likely be shaped by evolving regulatory expectations, technological advancements in manufacturing, and market dynamics.

• Increased Scrutiny on Supply Chain Transparency: Regulatory bodies and pharmaceutical companies are demanding greater transparency throughout the API supply chain, from raw material sourcing to final API release.
• Advancements in Continuous Manufacturing: While traditional batch manufacturing is prevalent, interest in continuous manufacturing processes for APIs is growing. This could offer benefits in terms of efficiency, quality control, and reduced footprint, potentially impacting omacetaxine mepesuccinate production in the long term.
• Emergence of New Generic Competitors: As patents expire in various regions, more generic manufacturers may seek to enter the market, leading to increased competition and a broader range of API suppliers.
• Focus on Green Chemistry and Sustainability: There will be increasing pressure on API manufacturers to adopt more environmentally sustainable manufacturing processes, reducing waste and solvent usage.
• Digitalization of Quality Management Systems: The adoption of digital tools for quality management, data integrity, and batch record keeping will become more prevalent, enhancing traceability and compliance.

Key Takeaways

• Omacetaxine mepesuccinate API supply is concentrated, with Bausch Health and specialized CDMOs as primary players.
• Strict adherence to cGMP, ICH guidelines, and comprehensive DMF filings are essential regulatory prerequisites.
• API specifications include rigorous controls on assay, impurities, water content, and residual solvents, often defined by pharmacopoeial monographs.
• The market is influenced by innovator control and the potential for generic competition, impacting pricing and supplier diversity.
• Sourcing requires thorough supplier qualification, assessment of regulatory support, robust quality agreements, and attention to supply chain security.
• Future trends point towards enhanced supply chain transparency, potential adoption of continuous manufacturing, and a greater focus on sustainability.

Frequently Asked Questions

• What is the primary therapeutic indication for omacetaxine mepesuccinate? Omacetaxine mepesuccinate is primarily indicated for the treatment of chronic myeloid leukemia (CML) in adult patients who have developed resistance or intolerance to prior tyrosine kinase inhibitor (TKI) therapy.
• Are there any known shortages or supply chain disruptions impacting omacetaxine mepesuccinate API availability? Specific real-time shortage data is proprietary and dynamic. Pharmaceutical companies must proactively monitor regulatory agency alerts (e.g., FDA Drug Shortages) and maintain close communication with their qualified API suppliers.
• How does the mepesuccinate salt form impact API characteristics? The mepesuccinate (mono-succinate) salt form is employed to improve the physicochemical properties of omacetaxine, such as solubility and stability, which are crucial for its formulation into a usable drug product.
• What are the key analytical techniques used for omacetaxine mepesuccinate API release testing? Typical release testing includes High-Performance Liquid Chromatography (HPLC) for assay and impurity profiling, Infrared (IR) spectroscopy for identification, Karl Fischer titration for water content, and Gas Chromatography (GC) for residual solvents.
• Can a generic drug manufacturer use an API produced by a supplier that only holds an API Master File (APIMF) in regions outside the US or EU? While an APIMF (equivalent to a DMF) is generally required, the specific acceptance criteria depend on the regulatory authority of the target market. For submission in the US and EU, a DMF or ASMF (Active Substance Master File) respectively, is typically necessary. Cross-referencing or ensuring acceptance by the relevant agency is paramount.

Citations

[1] Bausch Health Companies Inc. (n.d.). Omacetaxine Mepesuccinate. Retrieved from [relevant Bausch Health product or corporate website, if publicly available and specific to API production]. [2] U.S. Food and Drug Administration. (n.d.). Guidance for Industry: Drug Master Files. Retrieved from [FDA official website]. [3] European Medicines Agency. (n.d.). Active substance master file procedure. Retrieved from [EMA official website]. [4] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2009). ICH Harmonised Tripartite Guideline: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients Q7. Retrieved from [ICH official website]. [5] United States Pharmacopeia. (n.d.). Omacetaxine Mepesuccinate Monograph. (Access requires USP subscription). [6] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Active Substance Master File (ASMF) Procedure. Retrieved from [EDQM official website].